Paediatric Aggressive Mature B Cell Non-Hodgkin Lymphoma (Burkitt lymphoma)

- References

1) Patte, C. (2001). The Societe Francaise d’Oncologie pediatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood, 97(11), 3370–3379. https://doi.org/10.1182/blood.v97.11.3370

2) Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., Hoekstra, O. S., Hicks, R. J., O'Doherty, M. J., Hustinx, R., Biggi, A., & Cheson, B. D. (2014). Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(27), 3048–3058.

3) Sandlund JT, Guillerman RP, Perkins SL, et al. International pediatric non-Hodgkin lymphoma response criteria. J Clin Oncol 2015; 33:2106- 2111.

4) Sherief, A. M., Elsafy, U. R., Abdelkhalek, E. R., Kamal, N. M., Youssef, D. M., & Elbehedy, R. (2014). Disease patterns of pediatric non-Hodgkin Lymphoma: A Study from a developing area in Egypt. Molecular and Clinical Oncology, 3(1), 139–144. https://doi.org/10.3892/mco.2014.425

5) O'Rourke, E., Malone, A., O'Marcaigh, A., Storey, L., Betts, D., McDermott, M., & Smith, O. P. (2020). Burkitt Lymphoma/Leukaemia in Children & Young Adolescents. Irish medical journal, 113(1), 6.

6) Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of mature lymphoid neoplasms: A report from the Clinical Advisory Committee. Blood 2022;140:1229-1253.

7) Mhlanga J, Alazraki A, Cho SY, et al. Imaging recommendations in pediatric lymphoma: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper. Pediatr Blood Cancer 2022:e29968.

8) Abdel Rahman H, Sedky M, Hamoda A, et al. Role of FDG-PET scan in the management of pediatric mature B cell non-Hodgkin's lymphoma. CCHE experience. J Egypt Natl Canc Inst 2016;28:95-99.

9) Karantanis D, Durski JM, Lowe VJ, et al. 18F-FDG PET and PET/CT in Burkitt's lymphoma. Eur J Radiol 2010;75:e68-73.

10) Bailly C, Eugene T, Couec ML, et al. Prognostic value and clinical impact of (18)FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy. Front Med (Lausanne) 2014;1:54.

11) Cairo MS, Sposto R, Gerrard M, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol 2012;30:387-393.

12) Cairo M, Auperin A, Perkins SL, et al. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group. Br J Haematol 2018;182:859-869.

13)  Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin lymphoma: results of the FAB/LMB96 international study. Br J Haematol 2008; 141:840-847.

14) Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007;109:2773-2780.

15) Minard-Colin V, Aupérin A, Pillon M, et al. Rituximab for high-risk, mature B-cell non-Hodgkin's lymphoma in children. N Engl J Med 2020;382:2207-2219.

16) Frazer JK, Li KJ, Galardy PJ, et al. Excellent outcomes in children and adolescents with CNS(+) Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. Br J Haematol 2019; 185:374-377.

17) Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol 2014;167:394-401.

18) Cairo, M.S., Gerrard, M., Patte, C. et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood, 109, 2736–2743.

19) Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B- cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009;52:177-181.

20) Osumi T, Mori T, Fujita N, et al. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer 2016;63:1794-1799.

21) Eissa HM, Allen CE, Kamdar K, et al. Pediatric Burkitt's lymphoma and diffuse B-cell lymphoma: are surveillance scans required? Pediatr Hematol Oncol 2014;31:253-257.

22) Rosolen A, Perkins SL, Pinkerton CR, et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol 2015; 33:2112-2118.